Clark MA, Fisher C, Judson I, Thomas JM (2005) Soft-tissue sarcomas in adults. N Engl J Med 353(7):701–711

Article  CAS  PubMed  Google Scholar 

van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Schöffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet (London, England) 379(9829):1879–1886. https://doi.org/10.1016/S0140-6736(12)60651-5

Article  CAS  PubMed  Google Scholar 

Di Gion P, Kanefendt F, Lindauer A, Scheffler M, Doroshyenko O, Fuhr U, Wolf J, Jaehde U (2011) Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on pyrimidines, pyridines and pyrroles. Clin Pharmacokinet 50(9):551–603. https://doi.org/10.2165/11593320-000000000-00000

Article  PubMed  Google Scholar 

Helgadottir H, Bjornsson ES (2019) Problems associated with deprescribing of proton pump inhibitors. Int J Mol Sci 20(21):5469. https://doi.org/10.3390/ijms20215469

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sugano K (2018) Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date. Ther Adv Gastroenterol 11:1756283X17745776. https://doi.org/10.1177/1756283X17745776

Article  Google Scholar 

Tan AR, Gibbon DG, Stein MN, Lindquist D, Edenfield JW, Martin JC, Gregory C, Suttle AB, Tada H, Botbyl J, Stephenson JJ (2013) Effects of ketoconazole and esomeprazole on the pharmacokinetics of pazopanib in patients with solid tumors. Cancer Chemother Pharmacol 71(6):1635–1643. https://doi.org/10.1007/s00280-013-2164-3

Article  CAS  PubMed  Google Scholar 

Aoyama T, Nakano K, Yuasa T, Sugiyama E, Okawa T, Ito K, Azuma K, Hashimoto K, Furutani R, Hiraide M, Kobayashi K, Suzuki K, Tomomatsu J, Tajima M, Sato H, Hama T, Takahashi S (2023) Association between pazopanib exposure and safety in Japanese patients with renal cell carcinoma or soft tissue sarcoma. Sci Rep 13(1):2099. https://doi.org/10.1038/s41598-023-28688-9

Article  CAS  PubMed  PubMed Central  Google Scholar 

Verheijen RB, Bins S, Mathijssen RHJ, Lolkema MP, van Doorn L, Schellens JHM, Beijnen JH, Langenberg MHG, Huitema ADR, Steeghs N (2016) Individualized pazopanib dosing: a prospective feasibility study in cancer patients. Clin Cancer Res 22(23):5738–5746

Article  CAS  PubMed  Google Scholar 

Mir O, Touati N, Lia M, Litière S, Le Cesne A, Sleijfer S, Blay J-Y, Leahy M, Young R, Mathijssen RHJ, Van Erp NP, Gelderblom H, Van der Graaf WT, Gronchi A (2019) Impact of concomitant administration of gastric acid-suppressive agents and pazopanib on outcomes in soft-tissue sarcoma patients treated within the EORTC 62043/62072 Trials. Clin Cancer Res 25(5):1479–1485. https://doi.org/10.1158/1078-0432.CCR-18-2748

Article  CAS  PubMed  Google Scholar 

Moreau-Bachelard C, Letailleur V, Bompas E, Soulié P, Paul J, Raoul J-L (2022) Effect of concomitant proton pump inhibitors with pazopanib on cancer patients: a retrospective analysis. Cancers 14(19):47214. https://doi.org/10.3390/cancers14194721

Article  CAS  Google Scholar